# SCALLOP consortium - analysis plan for INF panel proteins

***Adapted from SCALLOP/CVD1 analysis plan, last updated 8/11/2018***

Timeline for completing cohort-specific analyses and uploading the results for this project --1 October 2018

## 1. Overview

The SCAndinavian coLLaboration for Olink plasma Protein genetics (SCALLOP) consortium, https://www.olink.com/scallop/, is a collaborative framework for discovery and follow-up of genetic associations with proteins on the Olink Proteomics platform. A meta-analysis has been conducted on data Olink CVD1 panel from participating cohorts and consequent contributions have been made on Olink INF panel. This document therefore follows closely the SCALLOP/CVD1 analysis plan for the analysis, and in particular highlights relevant information required to facilitate the meta-analysis.

As with the CVD1 meta-analysis, the tasks will involve

* Identification of pQTLs in SCALLOP discovery cohorts
* Replication of pQTLs in SCALLOP replication cohorts
* Investigation of the mechanistic basis of identified cis- and trans-pQTL by functional annotation
* Investigation of pleiotropic effects of the pQTLs
* Evaluation over the causal role of INF proteins disease outcomes such as CHD and stroke
* Other downstream analysis

## 2. Data and analysis

### Proteins

The Olink INFlammation panel of 92 proteins, e.g, https://github.com/jinghuazhao/INF/blob/master/doc/olink.inf.panel.annot.tsv.

### SNPs

* 1000 genomes imputation
* SNPs will be filtered for imputation quality at time of meta-analysis
* Quality control on aspects such as SNP/sample call rates, gender mismatch, abnormal inbreeding coefficient, failed cryptic relatedness test, ancestry outlier, heterozygosity and Hardy-Weinberg Equilibrium test.

### Association analysis

* Rank-based inverse normal transformation on the raw measurement of proteins including those below lower limit of detection, e.g., invnormal function,
* invnormal <- function(x)  
   qnorm((rank(x,na.last="keep")-0.5)/sum(!is.na(x)))
* Multiple linear regression for all samples including sex, age, principal components and other cohort specific covariates.
* Additive genetic model

### Stratification

* Analyse patients and controls separately – results will be merged at meta-analysis stage

### Software

It is preferable to use software which account for genotype uncertainty, such as SNPTEST, QUICKTEST, or BOLT-LMM.

## 3. Descriptive statistics

Please fill out the spreadsheet as with SCALLOP/CVD1 with naming convention:

* STUDY.descriptives.DATE.xls
* Where STUDY is a short (14 characters or less) identifier for the population studied, which is the same for all files provided by your study.
* DATE is the date on which the file was prepared, in the format “DDMMYYYY”.

## 4. File formats for GWAS results

### SNP table for GWAS results

Please include the following columns. Missing values are coded as “NA”.

|  |  |  |
| --- | --- | --- |
| No | Variable name | Description of variable |
| 1 | SNPID | SNP ID as rs number |
| 2 | CHR | Chromosome number (1-22) |
| 3 | POS | Physical position for the reference sequence (please indicate NCBI build in descriptive file) |
| 4 | STRAND | Indicator of strand direction. Please specify “+” if positive or forward strand and “-” if negative or reverse strand. |
| 5 | N | Number of non-missing observations |
| 6 | EFFECT\_ALLELE | Allele for which the effect (beta coefficient) is reported. For example, in an A/G SNP in which AA = 0, AG=1, and GG=2, the coded allele is G. |
| 7 | REFERENCE\_ALLELE | Second allele at the SNP (the other allele). In the example above, the non-coded allele is A. |
| 8 | CODE\_ALL\_FQ | Allele frequency for the coded allele – “NA” if not available |
| 9 | BETA | Effect size for the coded allele, beta estimate from the genotype-phenotype association, with at least 5 decimal places. Note: if not available, please report “NA” for this variable. |
| 10 | SE | Standard error of the beta estimate, to at least 5 decimal places - “NA” if not available. |
| 11 | PVAL | p-value of Wald test statistic – “NA” if not available |
| 12 | RSQ | Residual phenotypic variance explained by SNP. “NA” if not available |
| 13 | RSQ\_IMP | Observed divided by expected variance for imputed allele dosage. |
| 14 | IMP | Please specify whether the SNP was imputed or genotyped: 1: imputed SNP, 0: directly genotyped SNP |

### File-naming convention

It is recommended to use format STUDY\_analyst\_inf1\_protein\_UniProtID\_date.gz, see https://www.uniprot.org/ for additional information on UniProt IDs.

### Notes on PLINK

Due possibly to the large number of proteins for GWAS, some cohorts employed PLINK to expedite analysis with which one may see the following information:

|  |  |  |  |
| --- | --- | --- | --- |
| No | Name | Description | Additional comment |
| 1 | BP | Position in base pairs |
| 2 | CHR | Chromosome |
| 3 | SNP | SNP name/chr:pos\_a1\_a2 |
| 4 | HWE | Hardy-Weinberg equilibrium P-value |
| 5 | MAF | Minor allele frequency | Please indicate if this is the effect allele frequency |
| 6 | A1 | Allele 1 | Please indicate if this is the effect/reference allele |
| 7\* | A2 | Allele 2 | Please indicate if this is the effect/reference allele |
| 8 | N | Sample size |
| 9 | BETA | Regression coefficient |
| 10 | STAT | Regression test statistic |
| 11 | P | P value |

\* may be required to take from the PLINK .bim file.

In this case, please provide for each SNP information on strand, effect allele, effect allele frequency, and the information measures for imputation -- the information measure can be on the genotype level once for a cohort rather than from phenotype-genotype regression through software such as SNPTEST. SNP and sample based statistics can greatly be facilitated with software qctool, http://www.well.ox.ac.uk/~gav/qctool\_v2/.

## 5. Meta-analysis

Meta-analysis will be performed centrally using the inverse-N weighted analysis of regression betas and standard errors, as implemented in the software METAL (https://github.com/statgen/METAL).

We will apply genomic control and the appropriate marker filters at this stage (i.e. please provide unfiltered results).

* Marker exclusion filters: we will apply imputation quality filters at the meta-analysis stage, so provide unfiltered results.
* Genomic control (GC): genomic control will be applied to each study at the meta-analysis stage (single GC), so GC-correction is needed for each cohort.
* Significance: the threshold for the genome-wide analyses will be set at 5 x 10-10. The results will be replicated in independent cohorts.

## 6. Uploading of results

See the CVD1 analysis plan.

## 7. Contact information

For questions about SCALLOP, please contact Anders Malarstig (anders.malarstig@ki.se). For technical issues regarding TRYGGVE, please contact Lasse Folkersen (lasfol@cbs.dtu.dk).

For questions regarding SCALLOP/INF, please contact Jing Hua Zhao (jhz22@medschl.cam.ac.uk) and James Peters (jp549@medschl.cam.ac.uk).